Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study - Saba, Nabil F.; Hurwitz, Selwyn J.; Kono, Scott A.; Yang, Chung S.; Zhao, Yang; Chen, Zhengjia; Sica, Gabe; Müller, Susan; Moreno-Williams, Rachel; Lewis, Melinda; Grist, William; Chen, Amy Y.; et al. (Cancer prevention research (Philadelphia, Pa.), 2014)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - prevention & control; Celecoxib; Chemoprevention - methods; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms - metabolism; Head and Neck Neoplasms - prevention & control; Humans; Male; Medical sciences; Middle Aged; Miscellaneous; Otorhinolaryngology (head neck, general aspects and miscellaneous); Otorhinolaryngology. Stomatology; Prevention and actions; Public health. Hygiene; Public health. Hygiene-occupational medicine; Pyrazoles - administration & dosage; Pyrazoles - pharmacokinetics; Quinazolines - administration & dosage; Quinazolines - pharmacokinetics; Sulfonamides - administration & dosage; Sulfonamides - pharmacokinetics; Tumors; Antineoplastic agent; Prostaglandin-endoperoxide synthase; Chemoprophylaxis; Enzyme; Tyrosine kinase inhibitor; Quinazoline derivatives; Transferases; Enzyme inhibitor; Cyclooxygenase 2 inhibitor; Malignant tumor; Celecoxib; Non steroidal antiinflammatory agent; Prevention; Chemotherapy; Treatment; Erlotinib; ENT disease; Head and neck cancer; Oxidoreductases; Pharmacokinetics; Protein-tyrosine kinase; Cancer